Sodium bicarbonate
- Generic Name
- Sodium bicarbonate
- Brand Names
- Alka-seltzer, Alka-seltzer Fruit Chews, Alka-seltzer Heartburn Relief, Bi-peglyte, Bibag, Bicart, Bss Ophthalmic Solution, Ceo-two, Colyte, Gavilyte-C, Gavilyte-G, Gavilyte-H and Bisacodyl, Gavilyte-N, Golytely, H.E.L.P.bicel, Hema Bp-38, Hemacart, Konvomep, Nulytely, Peglyte, Phoxillum, Physioneal 40, Prismasol, Zegerid, Zegerid Reformulated Aug 2006, Zegerid With Magnesium Hydroxide
- Drug Type
- Small Molecule
- Chemical Formula
- CHNaO3
- CAS Number
- 144-55-8
- Unique Ingredient Identifier
- 8MDF5V39QO
- Background
Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.
- Indication
Sodium bicarbonate is used for the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Also is indicated in severe diarrhea which is often accompanied by a significan...
- Associated Conditions
- Barbiturate intoxication, Breast Cancer, Constipation, Dental Decay, Duodenal Ulcer, Dyspepsia, Gastro-esophageal Reflux Disease (GERD), Gingival Bleeding, Heartburn, Helicobacter Infections, Hyperkalemia, Ischaemia, Metabolic Acidosis, Myocardial Infarction, Plaque, Dental, Pruritis of the skin, Skin Irritation, Upper GI Bleeding, Upset stomach, Zollinger-Ellison Syndrome, Abdominal bloating, Benign, active Gastric Ulcer, Methyl alcohol poisoning, Prophylaxis of Contrast-induced nephropathy, Salicylate poisoning, Severe Diarrhea, Swelling of the gums
- Associated Therapies
- Bowel preparation therapy
FDA approves Azurity Pharmaceuticals' Danziten for CML treatment
FDA approves Azurity Pharmaceuticals’ Danziten (nilotinib), the first nilotinib formulation without mealtime restrictions, for treating chronic myeloid leukaemia (CML). Danziten offers equivalent efficacy to Tasigna with enhanced bioavailability and lower dosage, improving patient adherence by eliminating fasting requirements.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath